Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Total Non-Current Liabilities (2020 - 2025)

Oncology Institute (TOI) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $175.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 7.78% year-over-year to $175.9 million, compared with a TTM value of $175.9 million through Sep 2025, up 7.78%, and an annual FY2024 reading of $168.7 million, up 11.12% over the prior year.
  • Total Non-Current Liabilities was $175.9 million for Q3 2025 at Oncology Institute, up from $168.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $175.9 million in Q3 2025 and bottomed at $11.6 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $118.9 million, with a median of $144.7 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 798.21% in 2022, then dropped 2.54% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $99.3 million in 2021, then skyrocketed by 35.51% to $134.5 million in 2022, then rose by 12.87% to $151.8 million in 2023, then grew by 11.12% to $168.7 million in 2024, then increased by 4.24% to $175.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TOI at $175.9 million in Q3 2025, $168.8 million in Q2 2025, and $158.8 million in Q1 2025.